OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Carrie Wynn, Shou‐Ching Tang
Cancer and Metastasis Reviews (2022) Vol. 41, Iss. 1, pp. 193-209
Open Access | Times Cited: 48
Carrie Wynn, Shou‐Ching Tang
Cancer and Metastasis Reviews (2022) Vol. 41, Iss. 1, pp. 193-209
Open Access | Times Cited: 48
Showing 26-50 of 48 citing articles:
Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy
Zahra Shariaty Vaziri, Fatemeh Shafiee, Vajihe Akbari
Biotechnology Letters (2023) Vol. 45, Iss. 4, pp. 537-550
Closed Access | Times Cited: 4
Zahra Shariaty Vaziri, Fatemeh Shafiee, Vajihe Akbari
Biotechnology Letters (2023) Vol. 45, Iss. 4, pp. 537-550
Closed Access | Times Cited: 4
Quality-assured analysis of PIK3CA mutations in HR+/HER2- breast cancer tissue – A story about the need for proficiency testing for high-quality molecular biomarker reporting in precision medicine
Carolin Schmidt, Robert Stöhr, Lora Dimitrova, et al.
Journal of Molecular Diagnostics (2024) Vol. 26, Iss. 7, pp. 624-637
Open Access | Times Cited: 1
Carolin Schmidt, Robert Stöhr, Lora Dimitrova, et al.
Journal of Molecular Diagnostics (2024) Vol. 26, Iss. 7, pp. 624-637
Open Access | Times Cited: 1
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Alvan Cai, Yuan Chen, Lily S. Wang, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2635-2635
Open Access | Times Cited: 1
Alvan Cai, Yuan Chen, Lily S. Wang, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2635-2635
Open Access | Times Cited: 1
Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report
Yuanping Chen, Chao Liu, Xinglin Wen, et al.
International Journal of Women s Health (2024) Vol. Volume 16, pp. 1277-1283
Open Access | Times Cited: 1
Yuanping Chen, Chao Liu, Xinglin Wen, et al.
International Journal of Women s Health (2024) Vol. Volume 16, pp. 1277-1283
Open Access | Times Cited: 1
Epigenetic Biomarkers and the Wnt/β-Catenin Pathway in Opisthorchis viverrini-associated Cholangiocarcinoma: A Scoping Review on Therapeutic Opportunities
Alok Kafle, Sutas Suttiprapa, Mubarak Muhammad, et al.
PLoS neglected tropical diseases (2024) Vol. 18, Iss. 9, pp. e0012477-e0012477
Open Access | Times Cited: 1
Alok Kafle, Sutas Suttiprapa, Mubarak Muhammad, et al.
PLoS neglected tropical diseases (2024) Vol. 18, Iss. 9, pp. e0012477-e0012477
Open Access | Times Cited: 1
Real-world outcomes of pyrotinib-based therapy for HER2-positive breast cancer with brain metastases: A multicentre, retrospective analysis
Mindan Wu, Sen Lei, Yijing Tang, et al.
Clinical Breast Cancer (2024)
Closed Access | Times Cited: 1
Mindan Wu, Sen Lei, Yijing Tang, et al.
Clinical Breast Cancer (2024)
Closed Access | Times Cited: 1
Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer
Volkmar Müller, Thomas Bachelot, Giuseppe Curigliano, et al.
Cancer Treatment Reviews (2024) Vol. 132, pp. 102860-102860
Open Access | Times Cited: 1
Volkmar Müller, Thomas Bachelot, Giuseppe Curigliano, et al.
Cancer Treatment Reviews (2024) Vol. 132, pp. 102860-102860
Open Access | Times Cited: 1
ERBB2 as a prognostic biomarker correlates with immune infiltrates in papillary thyroid cancer
Yuchen Jin, Xian Qiu, Ziyan He, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 7
Yuchen Jin, Xian Qiu, Ziyan He, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 7
Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells
Anna Wawruszak, Estera Okoń, Ilona Telejko, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 5, pp. 1011-1024
Open Access | Times Cited: 6
Anna Wawruszak, Estera Okoń, Ilona Telejko, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 5, pp. 1011-1024
Open Access | Times Cited: 6
PTEN rs701848 Polymorphism is Associated with Trastuzumab Resistance in HER2-positive Metastatic Breast Cancer and Predicts Progression-free Survival
Nashwa El‐Khazragy, Ahmed Gaballah, Ashraf Bakkar, et al.
Clinical Breast Cancer (2022) Vol. 23, Iss. 3, pp. e131-e139
Closed Access | Times Cited: 6
Nashwa El‐Khazragy, Ahmed Gaballah, Ashraf Bakkar, et al.
Clinical Breast Cancer (2022) Vol. 23, Iss. 3, pp. e131-e139
Closed Access | Times Cited: 6
Targeting human EGFR 2 (HER2) in salivary gland carcinoma
Michael Wotman, Adel K. El‐Naggar, Renata Ferrarotto
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 6, pp. 573-582
Closed Access | Times Cited: 3
Michael Wotman, Adel K. El‐Naggar, Renata Ferrarotto
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 6, pp. 573-582
Closed Access | Times Cited: 3
Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer
Susanne Crocamo, Renata Binato, Everton Cruz dos Santos, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15515-15515
Open Access | Times Cited: 5
Susanne Crocamo, Renata Binato, Everton Cruz dos Santos, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15515-15515
Open Access | Times Cited: 5
Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer
Ana Carla Castro-Guijarro, Angel Matías Sanchez, Marina Inés Flamini
Cancers (2023) Vol. 15, Iss. 17, pp. 4374-4374
Open Access | Times Cited: 2
Ana Carla Castro-Guijarro, Angel Matías Sanchez, Marina Inés Flamini
Cancers (2023) Vol. 15, Iss. 17, pp. 4374-4374
Open Access | Times Cited: 2
A novel mutant PIK3R1EY451delinsD breast cancer patient resistant to HER2-targeted therapy treated with everolimus: a case report
Kainan Wang, Ye Hu, Lingzhi Xu, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 7, pp. 6155-6160
Closed Access | Times Cited: 3
Kainan Wang, Ye Hu, Lingzhi Xu, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 7, pp. 6155-6160
Closed Access | Times Cited: 3
A Comprehensive Review on the State of the Art of Breast Cancers in Italy
Domenico Iacopetta, Jessica Ceramella, Alessia Catalano, et al.
Current Medicinal Chemistry (2024) Vol. 31, Iss. 18, pp. 2486-2506
Open Access
Domenico Iacopetta, Jessica Ceramella, Alessia Catalano, et al.
Current Medicinal Chemistry (2024) Vol. 31, Iss. 18, pp. 2486-2506
Open Access
Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC
Feifei Li, Youyang Shi, Mei Ma, et al.
Journal of Pharmaceutical Analysis (2024) Vol. 14, Iss. 10, pp. 100977-100977
Open Access
Feifei Li, Youyang Shi, Mei Ma, et al.
Journal of Pharmaceutical Analysis (2024) Vol. 14, Iss. 10, pp. 100977-100977
Open Access
Análise do dispêndio financeiro do tratamento de Câncer de Mama com trastuzumabe durante o período da pandemia por COVID-19
Amanda Oliveira Serra-Campos, Hildeneide Rocha Lima, Mariana Ferreira Rodrigues de Souza, et al.
Brazilian Applied Science Review (2024) Vol. 8, Iss. 1, pp. 250-264
Open Access
Amanda Oliveira Serra-Campos, Hildeneide Rocha Lima, Mariana Ferreira Rodrigues de Souza, et al.
Brazilian Applied Science Review (2024) Vol. 8, Iss. 1, pp. 250-264
Open Access
Synergistic effect of the sphingosine kinase inhibitor safingol in combination with 2'-nitroflavone in breast cancer
Juan Manuel Anselmi Relats, Leonor P. Roguin, Mariel Marder, et al.
Journal of Molecular Medicine (2024) Vol. 102, Iss. 12, pp. 1503-1516
Closed Access
Juan Manuel Anselmi Relats, Leonor P. Roguin, Mariel Marder, et al.
Journal of Molecular Medicine (2024) Vol. 102, Iss. 12, pp. 1503-1516
Closed Access
Ocimum GratissimumLinn. Leaf Extract and Fractions Pre-Treatments are not Associated With Deleterious Electrocardiogram Changes inTrastuzumab-Intoxicated Wistar Rats
Adejuwon Adewale Adeneye, Olufunke E. Olorundare, Olumuyiwa Abiola Adejumobi, et al.
Al-Nahrain Journal of Science (2024) Vol. 27, Iss. 2, pp. 68-80
Open Access
Adejuwon Adewale Adeneye, Olufunke E. Olorundare, Olumuyiwa Abiola Adejumobi, et al.
Al-Nahrain Journal of Science (2024) Vol. 27, Iss. 2, pp. 68-80
Open Access
How does understanding epigenetics help circumvent HER-2 antibody resistance?
Débora Dummer Meira, Matheus Correia Casotti, André Felipe Monteiro Gonçalves, et al.
Elsevier eBooks (2024), pp. 95-126
Closed Access
Débora Dummer Meira, Matheus Correia Casotti, André Felipe Monteiro Gonçalves, et al.
Elsevier eBooks (2024), pp. 95-126
Closed Access
Trastuzumab Biosimilar ABP 980 Plus Pertuzumab and Docetaxel in the Therapy of Metastatic Breast Cancer: Real World Experiences from the National Research Institute of Oncology in Warsaw
Karolina Miacz, Agnieszka Jagiełło-Gruszfeld, Michał Kunkiel, et al.
(2022)
Open Access | Times Cited: 1
Karolina Miacz, Agnieszka Jagiełło-Gruszfeld, Michał Kunkiel, et al.
(2022)
Open Access | Times Cited: 1
Immunotherapy in breast cancer treatment
Pranav Bhaskar, Bijayani Sahu
(2022), pp. 190-209
Closed Access | Times Cited: 1
Pranav Bhaskar, Bijayani Sahu
(2022), pp. 190-209
Closed Access | Times Cited: 1
Characterising the role of neuropilin-1 in claudin-low breast cancer
Layla-Rose Lynam
(2023)
Open Access
Layla-Rose Lynam
(2023)
Open Access
